NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) screening 2 active_not_recruiting NCT02169284
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery treatment 2 terminated NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction treatment 1 active_not_recruiting NCT03047213
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations treatment 2 active_not_recruiting NCT02646319
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations treatment 0 completed NCT01522820
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors treatment 1 completed NCT01938573
Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer treatment 1 / 2 completed NCT00118040
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer treatment 2 completed NCT01050504
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer No drug interventions Not Available Not Available recruiting NCT02808143
Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer treatment 1 completed NCT02767921
sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer treatment 1 terminated NCT03229278
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma treatment 1 completed NCT00072137
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy treatment 1 terminated NCT02437370
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer treatment 1 completed NCT03552796
sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer treatment 1 withdrawn